CAJ | 학술논문

目的：探讨唑来膦酸联合化疗治疗晚期乳腺癌的疗效及对患者生活质量的影响。方法将2010年9月至2012年2月收治的晚期乳腺癌患者共60例，随机分为研究组与对照组，每组30例。研究组给予化疗联合唑来膦酸治疗；对照组除骨转移伴有明显疼痛者同时予以阿仑膦酸钠片口服外，均只应用化疗。对两组间的无进展生存期、总生存期、生活质量进行比较。结果在24个月随访周期后，研究组患者的无进展生存期优于对照组，差异有统计学意义（ P <0.05），但总生存期两组间差异无明显统计学意义（ P >0.05）。在生活质量方面，治疗后研究组的生活质量情况较对照组有较大的改善，其中，在躯体功能、总健康、疲倦、恶心呕吐、疼痛、气促和食欲丧失方面的表现优于对照组，差异有统计学意义（ P <0.05）。结论与化疗相比，唑来膦酸联合化疗能够显著延长晚期乳腺癌患者的无疾病进展期，并改善患者的生活质量。唑来膦酸联合化疗是治疗晚期乳腺癌有效且耐受性好的治疗方案。
목적：탐토서래련산연합화료치료만기유선암적료효급대환자생활질량적영향。방법장2010년9월지2012년2월수치적만기유선암환자공60례，수궤분위연구조여대조조，매조30례。연구조급여화료연합서래련산치료；대조조제골전이반유명현동통자동시여이아륜련산납편구복외，균지응용화료。대량조간적무진전생존기、총생존기、생활질량진행비교。결과재24개월수방주기후，연구조환자적무진전생존기우우대조조，차이유통계학의의（ P <0.05），단총생존기량조간차이무명현통계학의의（ P >0.05）。재생활질량방면，치료후연구조적생활질량정황교대조조유교대적개선，기중，재구체공능、총건강、피권、악심구토、동통、기촉화식욕상실방면적표현우우대조조，차이유통계학의의（ P <0.05）。결론여화료상비，서래련산연합화료능구현저연장만기유선암환자적무질병진전기，병개선환자적생활질량。서래련산연합화료시치료만기유선암유효차내수성호적치료방안。
Objective To observe on the curative effect of zoledronate combined chemotherapy phosphonic acid in the treatment of ad-vanced breast cancer. Methods 60 cases of metastatic breast cancer form September 2010 to February 2012 were randomly divided into study and control group,each group 30 cases. The study group was given chemotherapy and zoledronic acid treatment. The control group was given only chemotherapy except bone metastases associated with significant pain at the same time give oral alendronate sodium tablets. The progression-free survival,overall survival,quality of life were compared between the two groups. Results After a median follow-up of 24 months,the progression-free survival in study group was better than the control group. There was no difference in overall survival between the two groups( P >0. 05). The quality of life in the study group was improved significantly. The aspects of physical function,total health quality of life,fatigue,nausea and vomiting,pain,dyspnea and appetite in the study group were better than the control group. There were significant differencec between the two treatment groups( P <0. 05). Conclusion Compared with chemotherapy,zoledronic acid in combination with chemotherapy in metastatic breast cancer patients can improve the progression-free survival and their quality of life. This therapeutic strategy is an efficacious and tolerable adminis-tration mode for metastatic breast cancer patients.